

## Special Issue

# The Human Proteome in Disease, Diagnostics and Translation into Precision Medicine: Current Status and Future Prospects

### Message from the Guest Editor

It gives us great pleasure to invite researchers and scientists to this MDPI Special Issue by *Biomedicines*, which focuses on the human proteome in health, disease and therapy. Proteins are the primary functional effectors in human biology and are involved in health and diseases. The human proteoforms are rich and deciphering their structure/function is critical to both basic and translational research. It is very fitting and timely to launch this Special Issue as we celebrate 20 years of human proteome accomplishments and prepare for the next generation of advancements. Since the inception of the Human Proteome organization (HUPO) and its first World Congress in November 2002, the stated visionary goal has been translating the code of life. Undoubtedly, this will not only enhance our holistic understanding of human biology at the cellular/molecular levels but will also establish a foundation for the development of diagnostic, prognostic, therapeutic, and preventive medical applications. For marking the human proteome achievements, this *Biomedicines*' Special Issue aims to contribute to the knowledge of the human proteome.

### Guest Editor

Dr. M. Walid Qoronfleh

1. Q3 Research Institute (QRI), Research & Policy Division, Ann Arbor, MI 48197, USA
2. Consulting Services Department, 21 HealthStreet Ltd., London SW16 3JY, UK

### Deadline for manuscript submissions

closed (31 October 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/173343](https://mdpi.com/si/173343)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).